logo
Actelis Networks Reports First Quarter 2025 Financial Results With Stable Revenues Alongside Increased Global Partners Coverage And Operational Efficiency

Actelis Networks Reports First Quarter 2025 Financial Results With Stable Revenues Alongside Increased Global Partners Coverage And Operational Efficiency

Yahoo13-05-2025

Strategic focus on growing deal pipeline and high-margin wins drive gross margin expansion to 35% while maintaining stable revenues and disciplined cost management across growing global customer base
FREMONT, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the first quarter ended March 31, 2025.
"Our first quarter results are driven by both the continued execution of our focus on growing our pipeline for the remainder of the year, particularly in Federal, Military, our Multi-Dwelling Units business and in Intelligent Transportation, as well as on delivering improved margins and operational efficiency while working on the expansion of our presence in those key markets," said Tuvia Barlev, Chairman and CEO of Actelis. "We're particularly encouraged by our growing global footprint with this quarter seeing new orders from across the Nordic region, Hungary as well as others from the US, UK and Japan. These new orders validate the value proposition of our cyber-hardened, rapid deployment networking solutions and solidifies new business relationships we have established with major partners, integrators and distributors operating globally in NA, Europe, and Japan. Our ability to provide immediate fiber-grade connectivity over existing infrastructure, combined with our industry-leading security capabilities, continues to resonate strongly with customers seeking rapid, cost-effective solutions, enabling modernization and security for mission critical operations. We are properly focused on our growth areas and are geared towards an exciting year ahead."
First Quarter 2025 Financial Highlights:
Stable Revenues: Revenues were flat vs. the first three months ending March 31, 2024 at $0.72 million. Typically a lighter quarter seasonally, driven by the focus on growing the pipeline in advance of the remainder of the year.
Better Gross Margin: Gross margin improved to 35% for the first quarter ended March 31, 2025, compared to 30% for the first quarter ended March 31, 2024, reflecting higher gross margin across Federal and Military, higher US regional revenue weight, while maintaining operating cost discipline.
Operating expenses: 2.06 million for the three months ended March 31, 2025, 1.5% lower than $2.09 million for the three months ended March 31, 2024, reflecting the consistent efforts to reduce expenses.
Reduced Operating Loss: Operating loss improved to $1.81 million for the first quarter ended March 31, 2025, compared to $1.87 million in the year-ago period or a 3% improvement, driven by enhanced gross margins and continued expense control measures.
Strengthened Balance Sheet: The Company successfully improved its capital position during the quarter, bolstering shareholders' equity to $2.61 million, maintaining compliance with Nasdaq listing requirements.
Improved Net Loss Per Share: Net loss per share decreased to $(0.22) for the first quarter ended March 31, 2025, compared to $(0.50) in the year-ago period, a 56% improvement.
Recent Business and Operational Highlights:
Continued focus on our three main business areas of Federal and Military, Multi-Dwelling Units (MDU) and Intelligent Transportation Systems (ITS). Attention is particularly given to growing the pipeline in advance of the remainder of the year.
Global partners signed-up: Engaged with multi-billion Dollar partners - one global reseller and distributor, one multi-national pan European integrator and one Asian based multi-national large manufacturer and distributor to the transportation industry, generating opportunities for our ITS markets.
Progressed in resource strengthening: In our target verticals' sales and marketing, as well as in executing our off-shore, outsource strategy for better and lower cost operations, impacting R&D and G&A.
Military wins: Received new orders to deliver advanced GigaLine 800 (GL800) networking solution to help multi-billion dollar federal contractor modernize and cyber-harden military bases' operations for barracks, information centers, and other base-wide installations.
Nordic Municipal Expansion: Secured a new order to help modernize the communications infrastructure for a major city in the Nordic region, the second largest city in a prominent Nordic country with over 300,000 residents.
Hungarian Utility Project: Received a follow-on order from a Hungarian utility provider to support the continued modernization of its communications network, building upon the Company's previously announced engagement.
Japanese Market Growth: Received a new order to supply advanced networking technology to support critical infrastructure modernization in Japan through a leading Japanese distributor and developer of communications equipment.
Continued Military veteran consulting helps attract significant attention and build pipeline of opportunities in various DoD arms, particularly in the Air-Force
Pan-European sales presence expanding: MDU, ITS large pipeline opportunities progressing with agents deployed in various countries (Italy, Germany, France, UK, Finland, Italy and Poland)
Multi Dwelling Unit products completing successful trials and starting initial deployments with multiple carriers, ISP, and developers in multiple countries.
Yoav Efron, Deputy CEO and CFO of Actelis remarked: "We continue to strengthen our financial position through disciplined cost and expense management and strategic capital deployment. Our efforts to optimize operations are yielding results as seen in our improved margins and reduced expenses while effectively doing more in the market. We significantly decreased interest expenses as a result of becoming nearly debt free. We continue to focus on growing our recurring revenues and driving further margin expansion through our software and services as well as more profitable verticals' focus.'
Fiscal First Quarter 2025 Financial Results:
Revenues for the three months ended March 31, 2025, amounted to $721,000, compared to $726,000 for the three months ended March 31, 2024. The slight decrease was primarily due to a 31% decline in revenues from the Europe, Middle East, and Africa (EMEA) region. This was partially offset by a 23% increase in revenues from North America and growth in market size within the Asia-Pacific region.
Cost of revenues for the three months ended March 31, 2025, amounted to $470,000 compared to $506,000 for the three months ended March 31, 2024. The decrease was primarily attributable to the change in regional mix of revenue with an increase in North America revenues, which are more profitable, and a decrease in Europe, Middle East and Africa revenues which are less profitable.
Gross profit for the three months ended March 31, 2025, amounted to $251,000 or 35% of revenue, compared to $220,000, or 30% of revenue for the three months ended March 31, 2024. The increase was primarily due to improved regional revenue mix and efficient cost management.
Research and development expenses for the three months ended March 31, 2025, amounted to $681,000 compared to $647,000 for the three months ended March 31, 2024. The increase was primarily driven by a rise in the utilization of professional services.
Sales and marketing expenses for the three months ended March 31, 2025, amounted to $666,000 compared to $627,000 for the three months ended March 31, 2024. The increase was primarily by engaging consultants in the different regions.
General and administrative expenses for the three months ended March 31, 2025, amounted to $716,000 compared to $817,000 for the three months ended March 31, 2024. The decrease was mainly due to cost reduction measures taken.
Operating loss for the three months ended March 31, 2025, was $1.81 million, compared to an operating loss of $1.87 million for the three months ended March 31, 2024.
Financial expenses and interest expenses for the three months ended March 31, 2025, were $48,000 (including $34,000 interest expenses) compared to $115,000 (including $207,000 interest expenses) for the three months ended March 31, 2024. The decrease is mainly due to repayment of loans, reducing interest expense and other bank-related charges.
Net loss for the three months ended March 31, 2025, was $1.86 million, compared to net loss of $1.99 million for the three months ended March 31, 2024.
Adjusted EBITDA loss, a non-GAAP measurement of operating performance (reconciled below to Net Loss), for the three months ended March 31, 2025, was $1.69 million, compared to $1.79 million in the comparable year-ago period.
About Actelis Networks, Inc.Actelis Networks, Inc. (NASDAQ: ASNS) is a market leader in hybrid fiber-copper, cyber-hardened networking solutions for rapid deployment in wide-area IoT applications, including government, ITS, military, utility, rail, telecom, and campus networks. Actelis' innovative portfolio offers fiber-grade performance with the flexibility and cost-efficiency of hybrid fiber-copper networks. Through its 'Cyber Aware Networking' initiative, Actelis also provides AI-based cyber monitoring and protection for all edge devices, enhancing network security and resilience. For more information, please visit www.actelis.com.
Use of Non-GAAP Financial InformationNon-GAAP Adjusted EBITDA, and backlog of open orders are non-GAAP financial measures. In addition to reporting financial results in accordance with GAAP, we provide non-GAAP operating results adjusted for certain items, including: financial expenses, which are interest, financial instrument fair value adjustments, exchange rate differences of assets and liabilities, stock based compensation expenses, depreciation and amortization expense, tax expense, and impact of development expenses ahead of product launch. We adjust for the items listed above and show non-GAAP financial measures in all periods presented, unless the impact is clearly immaterial to our financial statements.
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Actelis is not responsible for the contents of third-party websites.
ContactARX | Capital Markets AdvisorsNorth American Equities Deskactelis@arxadvisory.com-Financial Tables to Follow-ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(U. S. dollars in thousands except for share and per share amounts)
March 31, 2025
December 31, 2024
Assets
CURRENT ASSETS:
Cash and cash equivalents
1,122
1,967
Restricted cash equivalents
302
300
Trade receivables, net of allowance for credit losses of $168 as of March 31, 2025, and December 31, 2024.
1,234
1,616
Inventories
2,508
2,436
Prepaid expenses and other current assets, net of allowance for doubtful debts of $181 as of March 31, 2025, and December 31, 2024.
681
584
TOTAL CURRENT ASSETS
5,847
6,903
NON-CURRENT ASSETS:
Property and equipment, net
35
38
Prepaid expenses and other
538
492
Restricted bank deposits
91
91
Severance pay fund
201
205
Operating lease right of use assets
310
410
Long-term deposits
85
86
TOTAL NON-CURRENT ASSETS
1,260
1,322
TOTAL ASSETS
7,107
8,225
F-3
ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (continued)UNAUDITED(U. S. dollars in thousands)
March 31, 2025
December 31, 2024
Liabilities, Mezzanine Equity and shareholders' equity
CURRENT LIABILITIES:
Credit line
444
774
Short-term loans
75
-
Trade payables
903
982
Deferred revenues
281
246
Employee and employee-related obligations
738
688
Accrued royalties
520
673
Current maturities of operating lease liabilities
298
415
Other current liabilities
481
805
TOTAL CURRENT LIABILITIES
3,740
4,583
NON-CURRENT LIABILITIES:
Long-term loan
150
150
Deferred revenues
69
92
Accrued severance
226
229
Other long-term liabilities
116
186
TOTAL NON-CURRENT LIABILITIES
561
657
TOTAL LIABILITIES
4,301
5,240
COMMITMENTS AND CONTINGENCIES (Note 5)
MEZZANINE EQUITY
Redeemable convertible preferred stock - $0.0001 par value, 10,000,000 authorized as of March 31, 2025 and December 31, 2024. None issued and outstanding as of March 31, 2025 and December 31, 2024.
-
-
WARRANTS TO PLACEMENT AGENT
228
228
SHAREHOLDERS' EQUITY:
Common stock, $0.0001 par value: 30,000,000 shares authorized: 9,019,758 and 7,623,159 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.
1
1
Non-voting common stock, $0.0001 par value: 2,803,774 shares authorized as of March 31, 2025, and December 31, 2024, None issued and outstanding as of March 31, 2025 and December 31, 2024.
-
-
Additional paid-in capital
48,499
46,818
Accumulated deficit
(45,922
)
(44,062
)
TOTAL SHAREHOLDERS' EQUITY
2,578
2,757
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY
7,107
8,225
The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).
F-4
ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)(U. S. dollars in thousands)
Three months endedMarch 31,
2025
2024
REVENUES
721
726
COST OF REVENUES
470
506
GROSS PROFIT
251
220
OPERATING EXPENSES:
Research and development expenses
681
647
Sales and marketing expenses
666
627
General and administrative expenses
716
817
TOTAL OPERATING EXPENSES
2,063
2,091
OPERATING LOSS
(1,812
)
(1,871
)
Interest expense
(34
)
(207
)
Other Financial income (expense), net
(14
)
92
NET COMPREHENSIVE LOSS FOR THE PERIOD
(1,860
)
(1,986
)
Net loss per share attributable to common shareholders – basic and diluted
$
(0.22
)
$
(0.50
)
Weighted average number of common stocks used in computing net loss per share – basic and diluted
8,520,110
3,978,828
The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).
F-5
ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY(UNAUDITED)U.S. dollars in thousands (except number of shares)
RedeemableConvertiblePreferred Stock
WarrantsToPlacement Agent
Common Stock
Non-votingCommon Stock
Additional
Total
Three months ended
Amount
Amount
Number of shares
Amount
Numberof shares
Amount
paid-incapital
Accumulateddeficit
shareholders'equity
BALANCE AS OF JANUARY 1, 2024
-
159
3,007,745
1
-
-
39,916
(39,688
)
229
Share based compensation
-
-
-
-
-
-
89
-
89
Vesting of RSUs
-
-
2,499
*
-
-
(*
)
-
-
Net comprehensive loss for the period
-
-
-
-
-
-
-
(1,986
)
(1,986
)
BALANCE AS OF MARCH 31, 2024
-
159
3,010,244
1
-
-
40,005
(41,674
)
(1,668
)
BALANCE AS OF JANUARY 1, 2025
-
228
7,623,159
1
-
-
46,818
(44,062
)
2,757
Share based compensation
-
-
-
-
-
-
79
-
79
Vesting of RSUs
-
-
1,665
*
-
-
(*)
-
-
Issuance of common stock, net of offering costs
-
-
1,394,934
*
-
-
1,580
1,580
Warrants to lender
-
-
-
-
-
-
22
-
22
Net comprehensive loss for the period
-
-
-
-
-
-
-
(1,860
)
(1,860
)
BALANCE AS OF March 31, 2025
-
228
9,019,758
1
-
-
48,499
(45,922
)
2,578
*
Represents an amount less than $1 thousand.
The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited)
F-6
ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)
Three months endedMarch 31,
2025
2024
U.S. dollars in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period
(1,860
)
(1,986
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
6
4
Inventories write-downs
5
-
Financial expenses (income)
15
(131
)
Share-based compensation
79
89
Financial income from short and long term bank deposit
-
(1
)
Changes in operating assets and liabilities:
Trade receivables
382
131
Net change in operating lease assets and liabilities
(22
)
6
Inventories
(76
)
(83
)
Prepaid expenses and other current assets
(94
)
91
Trade payables
(128
)
490
Deferred revenues
11
(87
)
Advances from reseller
-
1,143
Other current liabilities
(488
)
131
Other long-term liabilities
(4
)
-
Net cash used in operating activities
(2,174
)
(203
)
CASH FLOWS FROM INVESTING ACTIVITIES:
Short term deposits
1
-
Purchase of property and equipment
-
(1
)
Net cash provided by (used in) investing activities
1
(1
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance common stock
1,750
-
Offering cost from issuance of common stock
(170
)
-
Credit lines with bank, net
(324
)
574
Proceeds from short term loans
75
-
Early repayment of long term loan
-
(545
)
Repayment of long-term loan
-
(193
)
Net cash provided by (used in) financing activities
1,331
(164
)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS
(1
)
(2
)
DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS
(843
)
(370
)
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD
2,267
5,515
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD
1,424
5,145
The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).
F-7
ACTELIS NETWORKS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)(UNAUDITED)
March 31
2025
2024
U.S. dollars in thousands
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Cash and cash equivalents
1,122
1,211
Restricted cash equivalents, current
302
1,392
Restricted cash and cash equivalents, non-current
-
2,542
Total cash, cash equivalents and restricted cash
1,424
5,145
Three months endedMarch 31,
2025
2024
U.S. dollars in thousands
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest
167
273
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Warrant to lender
22
-
Other non-current assets
50
-
The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).
F-8
Three monthsEndedMarch 31,2025
Three monthsEndedMarch 31,2024
Revenues
$
721
$
726
GAAP net loss
(1,860
)
(1,986
)
Interest Expense
$
34
$
207
Other financial (income) expenses, net
14
(92
)
Tax Expense
32
17
Fixed asset depreciation expense
6
4
Stock based compensation
79
89
Research and development, capitalization
-
-
Other one time costs and expenses
-
(26
)
Non-GAAP Adjusted EBITDA
(1,695
)
$
(1,787
)
GAAP net loss margin
(257.97
)%
(273.55
)%
Adjusted EBITDA margin
(235.09
)%
(246.14
)%

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Growth Stocks to Stash and 1 to Question
2 Growth Stocks to Stash and 1 to Question

Yahoo

time24 minutes ago

  • Yahoo

2 Growth Stocks to Stash and 1 to Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.

Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology
Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology

Yahoo

time41 minutes ago

  • Yahoo

Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology

Head to Head Comparison 10X Tree of Life Basecamp Research_Cameroon Basecamp Research_CostaRica Uncharted Diversity Kmer Umap DNA Basecamp Research_Malta Company's multi-year biodiscovery programme, driven by strategic economic partnerships across 26 countries, has resulted in BaseDataTM the largest and fastest growing database of new biological protein sequences - 9.8 billion - ever built New species data gives scientists new potential therapeutic solutions to areas including antimicrobial resistance, gene editing, and environmental sustainability Scientific preprint demonstrates how BaseData breaks through biology's data wall and now exceeds the size, growth and diversity of public datasets that serve as the foundations for AI applications in the life sciences industry LONDON and CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Basecamp Research, an AI company dedicated to using nature to solve the most pressing challenges in the life sciences, today announced the discovery of over 1 million new species as part of BaseDataTM, the world's largest biological protein sequence database, and the first to be purpose-built to power the next era of generative biology. 'The rise of generative biology – using AI foundation models to design, generate, and annotate proteins, pathways and therapeutics – creates unprecedented demand for large, diverse biological sequence databases,' said Glen Gowers, Ph.D., CEO and Co-Founder of Basecamp Research. 'The million plus new species we've identified to date gives us an unrivaled understanding of how life on Earth has evolved over billions of years. We believe it will help the life sciences sector overcome today's critical data bottleneck and build a truly generative biology ecosystem with applications across nearly every area of human and planetary health.' Today, research relies heavily on public, open access biological sequence databases. Designed originally as academic collaboration tools, these databases are accessed over 100 million times per day and are the source of over 50% of all life science patents. This usage has grown by 10x in the last decade and continues to accelerate thanks in large part to the increasing use of data-hungry AI models in biopharma research. However, compared to all life on Earth, these databases are incomplete, riddled with redundancies, and highly-biased – 70% of all sequence data comes from just 10 species. Furthermore, the information in these databases is growing slowly, and companies using these databases for commercial purposes face increasing scrutiny on various legal fronts. This lack of growth and diversity holds back model performance and is a fundamental problem that slows research advancements in the life sciences: the data wall. Basecamp Research has broken through this data wall by pioneering an economic partnership-based model that incentivises the collection of samples across the planet's most extreme and biodiverse environments, working with 125+ communities in 26 countries. In a milestone disclosure, the company is unveiling the results of its biodiscovery initiative — BaseData has identified 9.8 billion new protein sequences. Once redundant sequences are removed, BaseData is currently over 10x bigger than all public databases combined. It continues to grow rapidly, offering a fundamentally new understanding of life on Earth. 'Biological foundation models are the key to continued progress in the life sciences, but their growth is slowing and performance is suffering,' said Oliver Vince, Ph.D., Co-Founder of Basecamp Research. 'It's this data wall that discourages life science teams in building and using huge biological foundation models. At Basecamp, we've demonstrated a new, scalable economic framework for expanding our knowledge of life on Earth and we show it is possible to overcome the data wall that's limiting progress for others in bioAI. Training our own foundation models on this data is enabling collaborations across the life sciences sector to help solve pressing challenges in drug discovery.' Basecamp Research scientists have uncovered more than one million new microbial species to date in some of the planet's most remote and extreme environments, expanding the view of the tree of life by over 10 times. The previously hidden biological insights in this data, combined with foundational AI models, will help shape everything from environmental sustainability and repair to therapeutics development. Examples of such newly discovered species include: On a World War II shipwreck, a new species of Burkholderia, a type of bacteria known for its ability to remove heavy metals from the environment. This could help improve pollution control and deepen our understanding of how bacteria resist antibiotics. In acidic hot springs near an active volcano, a new member of the Sulfolobaceae family that thrives in searing temperatures. Its specialized proteins, stress-response systems and stability near boiling point could help develop new ways to deliver medicine or preserve biological materials under harsh conditions. In Antarctic soil, a new species of Candidatus Eremiobacterota, a bacterium that survives by drawing nourishment from the air, generating its own water using hydrogen as an energy source — a finding that could inform novel gas-based drug delivery systems or therapeutic approaches. Basecamp Research is sharing further details in a pre-print paper and plans to offer early access to its unique data to life sciences researchers who express interest via its website to help them further their research. About Basecamp ResearchBasecamp Research is solving the most pressing challenges in the life sciences by exploring Beyond Known BiologyTM. We build foundational AI models on top of the world's largest, ethically-sourced database of biological information to give AI the most complete understanding of biology ever. This allows us to design more complex biological systems with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists and policy experts proudly work with more than 100 biodiversity partners across the globe, allowing us to deliver breakthroughs that can have a profound impact on healthcare and the lives of patients. Fast Company named Basecamp Research one of biotech's top 10 Most Innovative Companies in 2025. For more information, visit BaseDataTM and Beyond Known BiologyTM are brand names and technologies of Basecamp Research. Media Contact:Adam SilversteinSCIENT PRadam@ Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities
Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

Yahoo

timean hour ago

  • Yahoo

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

SOMERSET, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world's first free NCE-1 intelligence platform - built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time. Until now, tracking NCE exclusivity expirations and Paragraph IV filings has been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using spreadsheets. The result? Competitive blind spots, misaligned R&D, and a race already lost before it begins. For generic pharmaceutical companies aiming to be the 'first to file,' intelligence gaps, scattered data, and missed timelines can result in lost exclusivity and millions in revenue. NCE Grid changes Grid is the world's first free tool to integrate every critical data point, including molecule, innovator name, NCE-1 date, revenue, therapeutic usage, expected sales growth, and CAGR% into one intuitive platform. With real-time visualizations and actionable insights, NCE Grid empowers strategy, regulatory, and portfolio teams to identify, prioritize, and act on first-to-file opportunities with clarity and speed. 'We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,' said Salim Shaikh, Founder and CEO of Spring Bio Solution. 'In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — Your trusted guide for strategic drug development.' To learn more, visit About Spring Bio Solution Spring Bio Solution partners with CROs, pharmaceutical companies, and research institutions worldwide, offering reliable solutions for comparator sourcing and clinical trial supplies. With offices and WDL (wholesale Drug Distribution License) facilities across the USA, EU, Singapore, and India, and a robust network of 400+ distribution partners and 30+ innovators, Spring Bio Solution ensures timely and compliant access to critical drug supplies. Trusted by over 600 clients and maintaining a 99.9% success rate for sourcing comparator drugs/ RLDs/ innovator samples, the company offers industry-leading cold chain capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also ensures full DSCSA compliance and end-to-end traceability. With experience supporting over 1,000 clinical trials and more than 12,000 bioequivalence studies, Spring Bio Solution empowers sponsors to de-risk operations and accelerate drug development with confidence. For media inquiries, please contact: Navdeep TrivediVice President & Head, Digital MarketingSpring Bio in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store